Mubashra Khalid

Mubashra Khalid

Auto-generated profile, based on publicly available information

Mubashra Khalid

Allama Iqbal Medical College, Lahore, Pakistan

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

19 June 2023 in Nutrition
Verified
Journal Article
Closed access
ZKZoraiz Munir Khan
Zoraiz Munir Khan
MKMubashra Khalid
Mubashra Khalid
SKSatesh Kumar
Satesh Kumar

14 October 2023 in Digestive and Liver Disease
Verified
Journal Article
Closed access
NMNimra Masood
Nimra Masood
MKMubashra Khalid
Mubashra Khalid


24 May 2024 in Journal of the Pakistan Medical Association
Verified
Journal Article
Open access
PDF file
MMMisha Mansoor
Misha Mansoor
MSMuhammad Hamza Shafiq
Muhammad Hamza Shafiq
MKMubashra Khalid
Mubashra Khalid
Review articles highlighting importance of various issues in the domain of public health, drug and medical education

14 March 2025 in Research Square
Verified
Preprint
Open access
PDF file
HAHassaan Amin
Hassaan Amin
AAAiza Asif
Aiza Asif
FAFarooq Ahmad
Farooq Ahmad
SMSmaher Mustafa
Smaher Mustafa
MKMubashra Khalid
Mubashra Khalid
AKAbdur Rehman Khalid
Abdur Rehman Khalid
Objectives Ventricular tachycardia (VT) in ischemic heart disease (IHD) carries a high risk of sudden cardiac death. Treatment typically involves catheter ablation or antiarrhythmic drugs (AADs), but the optimal approach is uncertain. This meta-analysis compared the safety of these treatments for VT in IHD patients. Methods This meta-analysis included all studies comparing catheter ablation with AADs in IHD patients with symptomatic VT. Databases searched included PubMed, Google Scholar, Embase, and Cochrane Library up to June 9, 2024. Primary outcomes analyzed were recurrent VT, mortality, and heart failure; secondary outcomes included hospitalizations for VT, VT storm, and appropriate anti-tachycardia pacing (AATP). Risk ratios (RR) with 95% confidence intervals (CI) were calculated using a random-effects model. Quality and bias were assessed using the Cochrane ROB 2 tool, and heterogeneity with Higgins I² statistic. Results Three studies with 430 participants were included. No significant difference was found between ablation and AADs for recurrent VT (RR = 1.08; 95%CI = 0.70–1.65; p = 0.74; I²=0%), mortality (RR = 0.98; 95%CI = 0.67–1.42; p = 0.90; I²=0%), and AATP (RR = 1.00; 95%CI = 0.84–1.20; p = 0.97; I²=0%).Heart failure (RR = 0.75; 95%CI = 0.50–1.11; p = 0.15; I²=0%), VT storm (RR = 0.77; 95%CI = 0.55–1.09; p = 0.14; I²=0%), and hospitalizations for VT (RR = 0.59; 95% CI = 0.30–1.15; p = 0.12; I²=62%) were lower with ablation but not significantly. Conclusion While no significant differences emerged, ablation showed a trend toward reducing heart failure and hospitalizations, suggesting potential advantages in managing VT-related complications in IHD. Further large-scale studies are needed to confirm these benefits.